New Insight into the Treatment of Primary Myelofibrosis

Nahla AM Hamed
Additional contact information
Nahla AM Hamed: Professor of Hematology, Hematology Department, Alexandria University, Egypt

Cancer Therapy & Oncology International Journal, 2018, vol. 12, issue 5, 10-12

Abstract: PMF belongs to the category of myeloproliferative neoplasm. It has a chronic disabling course and shortened survival. The prognostic scores IPSS, DIPSS and DIPSS-plus, do not perform as well for post-ET or post-PV MF patients. Three new prognostic systems have been recently introduced: GIPSS based exclusively on mutations and karyotype, MIPSS70 is best utilized in the absence of cytogenetic information but presence of molecular information

Keywords: juniper publishers:oncology journals; oncology research journals; oncology journal articles; oncology and cancer case reports; oncology journal of clinical and experimental cancer research; open access; open access journals; Oncology International Journal; juniper publishers reivew (search for similar items in EconPapers)
Date: 2018
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://juniperpublishers.com/ctoij/pdf/CTOIJ.MS.ID.555847.pdf (application/pdf)
https://juniperpublishers.com/ctoij/CTOIJ.MS.ID.555847.php (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:adp:jctoij:v:12:y:2018:i:5:p:10-12

DOI: 10.19080/CTOIJ.2018.12.555847

Access Statistics for this article

Cancer Therapy & Oncology International Journal is currently edited by Sophia Mathis

More articles in Cancer Therapy & Oncology International Journal from Juniper Publishers Inc.
Bibliographic data for series maintained by Robert Thomas ().